Organon downgraded by BofA Securities with a new price target
$OGN
Biotechnology: Pharmaceutical Preparations
Health Care
BofA Securities downgraded Organon from Buy to Neutral and set a new price target of $37.00 from $40.00 previously
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/27/2025 | $5.00 | Overweight → Underweight | Piper Sandler |
| 5/2/2025 | Outperform → In-line | Evercore ISI | |
| 9/6/2024 | $18.00 → $20.00 | Neutral → Underweight | JP Morgan |
| 11/3/2023 | $33.00 → $16.00 | Buy → Neutral | Goldman |
| 9/21/2023 | $28.00 | Overweight | Barclays |
| 3/16/2023 | $33.00 | Outperform | Raymond James |
| 10/14/2022 | $27.00 → $25.00 | Neutral → Underperform | BofA Securities |
| 9/6/2022 | $37.00 → $34.00 | Neutral → Overweight | Piper Sandler |
Sub-analysis of children with atopic dermatitis aged 2-17 in pivotal Phase 3 trials revealed early and clinically meaningful improvements in vIGA-AD™ and EASI-75 (skin clearance and severity), POEM (patient-reported outcomes) and PP-NRS (itch), regardless of comorbidity status, at week 8 Organon (NYSE:OGN), a global independent healthcare company with a focus on women's health, will present results from a sub-analysis of pooled data from the Phase 3 ADORING 1 and ADORING 2 pivotal trials evaluating VTAMA cream versus vehicle at the 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in Orlando, Florida, on November 8, 2025. The new data demonstrate tha
Net proceeds will be applied to debt reduction, advancing Organon's ongoing deleveraging efforts Positions Organon for future investment in growth opportunities with a focus on women's health biopharma and other strategic priorities Laborie's capabilities in medical technology will facilitate broader access to JADA for more mothers Organon (NYSE:OGN), ("Organon" or "the Company") a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has entered into an agreement with Laborie Medical Technologies Corp. ("Laborie"), a leading diagnostic and therapeutic medical technology company, for them to acquire th
Organon (NYSE:OGN), a global healthcare company with a primary focus on women's health, will release its third quarter 2025 financial results on November 10, 2025, prior to the company's webcast and conference call scheduled for 8:30 a.m. ET. The webcast and conference call will be hosted by Carrie Cox, Organon's Executive Board Chair; Joe Morrissey, Interim Chief Executive Officer; and Matt Walsh, Chief Financial Officer. IPR&D and Milestones The company will not record any milestone expense in the third quarter of 2025. Accessing Third Quarter 2025 Financial Results Webcast Interested parties may access the live call via webcast on the Organon website at https://www.organon.com/inves
8-K - Organon & Co. (0001821825) (Filer)
8-K/A - Organon & Co. (0001821825) (Filer)
SCHEDULE 13G/A - Organon & Co. (0001821825) (Subject)
4 - Organon & Co. (0001821825) (Issuer)
4 - Organon & Co. (0001821825) (Issuer)
4 - Organon & Co. (0001821825) (Issuer)
Piper Sandler downgraded Organon from Overweight to Underweight and set a new price target of $5.00
Evercore ISI downgraded Organon from Outperform to In-line
JP Morgan downgraded Organon from Neutral to Underweight and set a new price target of $20.00 from $18.00 previously
4 - Organon & Co. (0001821825) (Issuer)
4 - Organon & Co. (0001821825) (Issuer)
4 - Organon & Co. (0001821825) (Issuer)
Organon (NYSE:OGN) ("Organon" or "the company") today announced that its Board of Directors has appointed the Company's Executive Vice President and Head of Manufacturing & Supply, Joseph Morrissey, Interim Chief Executive Officer. Board Chair Carrie S. Cox will also take on additional responsibilities on an interim basis as Executive Chair to support Mr. Morrissey in his new role. Director Robert Essner will assume the role of Lead Independent Director. These appointments follow the resignation of Kevin Ali as Chief Executive Officer and member of the Board in connection with the Audit Committee investigation described below. Mr. Ali has agreed that he will not be entitled to severance o
Organon (NYSE:OGN) a global healthcare company with a focus on women's health, today announced the appointment of Ramona A. Sequeira, President of the Global Portfolio Division at Takeda Pharmaceutical Company, to Organon's Board of Directors, effective July 1, 2025. Ms. Sequeira will serve on the Board's Talent Committee. In connection with Ms. Sequeira's appointment, the size of Organon's Board will be expanded to 12 directors. Ms. Sequeira brings more than 30 years of pharmaceutical industry expertise, with 20 years at Eli Lilly and Company and 10 years at Takeda. She is a proven commercial leader with a steadfast commitment to building strategies around the needs of patients and a trac
Leadership transition comes as Company focuses on clinical evaluation of its novel Ovarian Rebalancing™ technology, a one-time transvaginal ablation procedure designed to restore ovulation in women with PCOS, a leading cause of infertility PARIS, March 10, 2025 /PRNewswire/ -- May Health, a Paris- and California-based, clinical-stage medical device company dedicated to the development of a new treatment for Polycystic Ovary Syndrome (PCOS), today announced that Colby Holtshouse has joined the Company as President and CEO. Colby brings a wealth of senior leadership and women's health expertise to the organization, having held executive positions with Organon (NYSE:OGN), Alydia Health, and Pel
Organon (NYSE:OGN), a global healthcare company with a primary focus on women's health, will release its third quarter 2025 financial results on November 10, 2025, prior to the company's webcast and conference call scheduled for 8:30 a.m. ET. The webcast and conference call will be hosted by Carrie Cox, Organon's Executive Board Chair; Joe Morrissey, Interim Chief Executive Officer; and Matt Walsh, Chief Financial Officer. IPR&D and Milestones The company will not record any milestone expense in the third quarter of 2025. Accessing Third Quarter 2025 Financial Results Webcast Interested parties may access the live call via webcast on the Organon website at https://www.organon.com/inves
Second quarter 2025 revenue of $1.594 billion Second quarter 2025 diluted earnings per share of $0.56 and non-GAAP Adjusted diluted earnings per share of $1.00; GAAP diluted earnings per share includes a $46 million gain, or $0.14 per share, for early extinguishment of debt Second quarter 2025 net income of $145 million and Adjusted EBITDA (non-GAAP) of $522 million, representing an Adjusted EBITDA margin of 32.7% The company repaid $345 million of long-term debt during the quarter; on track to achieve a net debt to Adjusted EBITDA ratio of less than 4.0x by year-end Revenue guidance range for full year 2025 raised to $6.275 billion to $6.375 billion based on the company's curr
Organon (NYSE:OGN), a global healthcare company with a primary focus on women's health, will release its second quarter 2025 financial results on August 5, 2025, prior to the company's webcast and conference call scheduled for 8:30 a.m. EDT. Accessing Second Quarter 2025 Financial Results Webcast Interested parties may access the live call via webcast on the Organon website at https://www.organon.com/investor-relations/events-and-presentations/. A replay of the webcast will be available approximately two hours after the conclusion of the live event on the company's website. Institutional investors and analysts interested in participating in the call may join by dialing (888) 596-4144
SC 13G/A - Organon & Co. (0001821825) (Subject)
SC 13G/A - Organon & Co. (0001821825) (Subject)
SC 13G/A - Organon & Co. (0001821825) (Subject)